title: Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
abstract: The "sandwich" protocol, was first proposed by us and comprised of l-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy, results in 2-year overall survival and progression-free survival rates that surpass traditional therapies for patients with newly diagnosed, stage IE-IIE, nasal type, extranodal natural killer/T-cell lymphoma. The results had been published by cancer. These patients were followed up over a median period of 67 months, for which updates and the results of prognostic factors analyses are presented. The 5-year overall survival and progress-free survival rates were both 64%. The highest rates of death occurred during the first 6 months, and between the second and third year after enrollment. The initial therapeutic response (odds ratio = 5.83; P = 0.001) and B symptoms (odds ratio = 6.13; P = 0.043) were significant prognostic factors for overall survival. However, the international prognostic index was not significant for progress-free survival and overall survival. There were no severe long-term side effects. These results indicate that the "sandwich" protocol may benefit the long-term survival of patients with newly diagnosed stage IE-IIE, nasal type, extranodal natural killer/T-cell lymphoma. However, additional studies with larger samples are required to confirm these results. This study is registered at www.Chictr.org (ChicTR-TNC-09000394).
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.|Department of Oncology, Dujiangyan Medical Center, Dujiangyan, Sichuan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Jiang
authors.affiliation: Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xie
authors.affiliation: Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Pathology Department, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Qun-pei
authors.initials: QP
authors.lastname: Yang
authors.affiliation: Pathology Department, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Liu
authors.affiliation: Pathology Department, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Wen-yan
authors.initials: WY
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Hong-yu
authors.initials: HY
authors.lastname: Zhuo
authors.affiliation: Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Li
authors.affiliation: Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Nian-yong
authors.initials: NY
authors.lastname: Chen
authors.affiliation: Pathology Department, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Sha
authors.initials: S
authors.lastname: Zhao
authors.affiliation: Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Li-qun
authors.initials: LQ
authors.lastname: Zou
mesh_terms: D000328:Adult; D059248:Chemoradiotherapy / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D017211:Treatment Failure; D016896:Treatment Outcome; D055815:Young Adult
keywords: Chemoradiotherapy; extranodal natural killer/T-cell lymphoma; l-asparaginase prednisone; long-term survival; prognostic factors; vincristine